Dr. Doris E. Estrada, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
DC license MD046826
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 14 payments worth $9,204 in total to this clinician.
| Soleno Therapeutics, Inc. | $8,993 |
|---|---|
| Mannkind Corporation | $123 |
| Dexcom, Inc. | $29.58 |
| Sequel Med Tech, LLC | $23.46 |
| Xeris Pharmaceuticals, Inc. | $20.25 |
| Sanofi-aventis U.S. LLC | $14.77 |
| Consulting Fee | $7,200 |
|---|---|
| Travel and Lodging | $1,264 |
| Food and Beverage | $740 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Soleno Therapeutics, Inc. Oct 30, 2025 | Consulting Fee VYKAT XR · Prader-Willi syndrome | $7,200 |
| Soleno Therapeutics, Inc. Oct 3, 2025 | Travel and Lodging VYKAT XR · Prader-Willi syndrome · travel to Denver, CO · in-kind | $987 |
| Soleno Therapeutics, Inc. Oct 3, 2025 | Travel and Lodging VYKAT XR · Prader-Willi syndrome · travel to Denver, CO · in-kind | $277 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16.00 in research payments for these studies, mostly to the institutions running them.
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company · Recruiting · NCT06739122
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.